Phio Pharmaceuticals Corp. (PHIO)
1.09
-0.02
(-1.80%)
USD |
NASDAQ |
Sep 04, 11:31
Phio Pharmaceuticals Research and Development Expense (Annual) : 4.618M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 4.618M |
| December 31, 2024 | 3.643M |
| December 31, 2023 | 6.332M |
| December 31, 2022 | 7.012M |
| December 31, 2021 | 8.886M |
| December 31, 2020 | 4.431M |
| December 31, 2019 | 4.30M |
| Date | Value |
|---|---|
| December 31, 2018 | 4.326M |
| December 31, 2017 | 5.37M |
| December 31, 2016 | 5.415M |
| December 31, 2015 | 6.925M |
| December 31, 2014 | 5.68M |
| December 31, 2013 | 17.65M |
| December 31, 2012 | 10.45M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Imunon, Inc. | 7.781M |
| Agenus, Inc. | 79.34M |
| Amgen, Inc. | 6.974B |
| Anika Therapeutics, Inc. | 25.77M |
| BioCryst Pharmaceuticals, Inc. | 164.74M |